Biotech Drug Development Clinical Programs The CompanyDimerix Limited (ASX: DXB), is a Melbourne-based clinical-stage biopharmaceutical company developing patient-preferred treatments for unmet needs in kidney and inflammatory diseases. Its pipeline includes lead asset DMX-200 for FSGS, diabetic kidney disease and ARDS, and DMX-700 for COPD. Working with global partners, CROs, CDMOs and specialist consultants, Dimerix is a small, collaborative, values-led team at an exciting stage of clinical ...
Insert additional messaging here.
